AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Hill-Rom's (HRC) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Hill-Rom's (HRC) first-quarter fiscal 2021 revenue climbed 8.2% year over year to $741.1 million.
Why Is AngioDynamics (ANGO) Up 8.7% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results reflect strong segmental performance.
Zacks.com featured highlights include: AngioDynamics, ICICI Bank, LG Display Co and Mayville Engineering
by Zacks Equity Research
Zacks.com featured highlights include: AngioDynamics, ICICI Bank, LG Display Co and Mayville Engineering
Becton Dickinson (BDX) Earnings Surpass Estimates in Q1
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.
Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows
by Zacks Equity Research
Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.
Change Healthcare (CHNG) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance in the Network Solutions segment.
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.
AmerisourceBergen (ABC) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.
Grab These 4 Breakout Stocks for Spectacular Gains
by Nitish Marwah
In case a stock falls below the lower bound of this band, it may be time to offload it from your portfolio.
Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.
Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline
by Zacks Equity Research
Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from strong segmental performance.
Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts
by Zacks Equity Research
Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.
IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.
AngioDynamics' (ANGO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AngioDynamics (ANGO).